US 11,999,683 B2
Lipocationic dendrimers and uses thereof
Daniel J. Siegwart, Dallas, TX (US); and Kejin Zhou, Dallas, TX (US)
Assigned to The Board of Regents of The University of Texas System, Austin, TX (US)
Filed by The Board of Regents of The University of Texas System, Austin, TX (US)
Filed on Jun. 15, 2023, as Appl. No. 18/335,960.
Application 18/335,960 is a continuation of application No. 17/566,666, filed on Dec. 30, 2021, granted, now 11,858,884.
Application 17/566,666 is a continuation of application No. 15/265,064, filed on Sep. 14, 2016, granted, now 11,247,968, issued on Feb. 15, 2022.
Claims priority of provisional application 62/218,412, filed on Sep. 14, 2015.
Prior Publication US 2024/0043378 A1, Feb. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 321/14 (2006.01); A61K 9/51 (2006.01); A61K 31/7105 (2006.01); A61K 31/7125 (2006.01); A61K 47/20 (2006.01); A61K 47/22 (2006.01); A61K 47/59 (2017.01); A61K 47/60 (2017.01); A61K 47/69 (2017.01); A61K 48/00 (2006.01); C07C 323/52 (2006.01); C07D 295/15 (2006.01)
CPC C07C 321/14 (2013.01) [A61K 9/513 (2013.01); A61K 9/5146 (2013.01); A61K 31/7105 (2013.01); A61K 31/7125 (2013.01); A61K 47/20 (2013.01); A61K 47/22 (2013.01); A61K 47/59 (2017.08); A61K 47/60 (2017.08); A61K 47/6931 (2017.08); A61K 48/0041 (2013.01); C07C 323/52 (2013.01); C07D 295/15 (2013.01)] 20 Claims
 
1. A compound that is a compound of Formula (I):
Core-Repeating Unit-Terminating Group (I),
or a pharmaceutically acceptable salt thereof, wherein the core is linked to four repeating units and each repeating unit is linked to a nitrogen of the core, wherein the core has the following structure:

OG Complex Work Unit Chemistry
wherein each repeating unit is a degradable diacyl, having the formula

OG Complex Work Unit Chemistry
wherein in Formula (VII),
A1 and A2 are each —O—;
Y3 is alkanediyl(C≤12);
R9 is alkanediyl(C≤8); and
the terminating group is:

OG Complex Work Unit Chemistry
wherein Y4 is alkanediyli(C≤18) and R10 is H.